Edwards Lifesciences (EW) Stock Forecast & Price Target

$66.58

+0.81 (+1.23%)

(As of 09/27/2024 ET)

Edwards Lifesciences - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Hold

Based on 27 Analyst Ratings

Sell
0

Hold
15

Buy
12

Based on 27 Wall Street analysts who have issued ratings for Edwards Lifesciences in the last 12 months, the stock has a consensus rating of "Hold." Out of the 27 analysts, 15 have given a hold rating, 11 have given a buy rating, and 1 has given a strong buy rating for EW.

Consensus Price Target

$79.82
19.88% Upside

According to the 27 analysts' twelve-month price targets for Edwards Lifesciences, the average price target is $79.82. The highest price target for EW is $106.00, while the lowest price target for EW is $57.00. The average price target represents a forecasted upside of 19.88% from the current price of $66.58.

EW Analyst Ratings Over Time

Type	Current Forecast 9/29/23 to 9/28/24	1 Month Ago 8/30/23 to 8/29/24	3 Months Ago 7/1/23 to 6/30/24	1 Year Ago 9/29/22 to 9/29/23
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	11 Buy rating(s)	11 Buy rating(s)	14 Buy rating(s)	9 Buy rating(s)
Hold	15 Hold rating(s)	13 Hold rating(s)	5 Hold rating(s)	8 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	1 Sell rating(s)	1 Sell rating(s)
Consensus Price Target	$79.82	$82.10	$95.06	$92.30
Forecasted Upside	19.88% Upside	17.08% Upside	2.91% Upside	33.23% Upside
Consensus Rating	Hold	Moderate Buy	Moderate Buy	Hold

NOTICE: You have until Tuesday, November 19th (Ad)

On Tuesday, November 19, 2024 smart investors will collect their share of a $1.2 billion windfall... It's part of a unique strategy which has nothing to do with risky investments like options, cryptos or forex. And while it might sound crazy...

Click here for the ticker >>>

EW Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

EW Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Edwards Lifesciences Stock vs. The Competition

Type	Edwards Lifesciences	Medical Companies	S&P 500
Consensus Rating Score	2.48	2.78	2.50
Consensus Rating	Hold	Moderate Buy	Hold
Predicted Upside	19.88% Upside	818.42% Upside	6.14% Upside
News Sentiment Rating	Positive News See Recent EW News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
9/18/2024	Jefferies Financial Group 2 of 5 stars		Downgrade	Buy ➝ Hold	$85.00 ➝ $70.00	+4.14%
9/13/2024	Truist Financial 1 of 5 stars		Lower Target	Hold ➝ Hold	$82.00 ➝ $71.00	+1.23%
9/12/2024	Oppenheimer 3 of 5 stars		Reiterated Rating	Outperform ➝ Outperform	$90.00 ➝ $90.00	+34.71%
9/10/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral ➝ Neutral	$90.00 ➝ $75.00	+12.66%
9/9/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$90.00 ➝ $80.00	+21.34%
9/9/2024	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$90.00 ➝ $80.00	+19.47%
NOTICE: You have until Tuesday, November 19th (Ad) On Tuesday, November 19, 2024 smart investors will collect their share of a $1.2 billion windfall... It's part of a unique strategy which has nothing to do with risky investments like options, cryptos or forex. And while it might sound crazy... Click here for the ticker >>>
7/31/2024	Daiwa America Subscribe to MarketBeat All Access for the recommendation accuracy rating	N. Nakagiri Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
7/31/2024	Daiwa Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Neutral ➝ Outperform
7/29/2024	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Polark Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Underperform ➝ Peer Perform
7/26/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$107.00 ➝ $91.00	+44.72%
7/25/2024	Baird R W Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. Rescott Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
7/25/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	J. Jennings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold	$100.00 ➝ $70.00	+14.27%
7/25/2024	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	In-Line ➝ In-Line	$91.00 ➝ $76.00	+22.50%
7/25/2024	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$101.00 ➝ $85.00	+34.60%
7/25/2024	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$103.00 ➝ $85.00	+34.60%
7/25/2024	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Hold ➝ Hold	$85.00 ➝ $70.00	+3.61%
7/25/2024	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Hold ➝ Hold	$85.00 ➝ $77.00	-11.44%
7/25/2024	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral ➝ Neutral	$88.00 ➝ $73.00	-16.04%
7/25/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Neutral	$105.00 ➝ $75.00	-13.74%
7/25/2024	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Outperform ➝ Neutral	$102.00 ➝ $70.00	-19.49%
7/25/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Overweight ➝ Neutral	$105.00 ➝ $72.00	-17.19%
7/10/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$105.00 ➝ $106.00	+13.03%
4/11/2024	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$95.00 ➝ $105.00	+14.78%
3/26/2024	OTR Global Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Mixed ➝ Positive
3/21/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$95.00 ➝ $103.00	+8.72%
10/16/2023	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Kratky Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform
10/16/2023	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Market Perform	$75.00	+4.90%
6/27/2023	58.com Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Reiterates
2/6/2023	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Outperform ➝ Market Perform
1/31/2023	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Outperform ➝ Underperform	$95.00 ➝ $66.00	-13.23%
10/28/2022	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$125.00 ➝ $100.00	+38.85%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 01:05 PM ET.

Should I Buy Edwards Lifesciences Stock? EW Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Monday, September 9, 2024. Please send any questions or comments about these Edwards Lifesciences pros and cons to contact@marketbeat.com.

Edwards Lifesciences
Bull Case

Here are some ways that investors could benefit from investing in Edwards Lifesciences Co.:

Edwards Lifesciences Co. has a strong track record of consistent revenue growth, indicating stability and potential for future earnings.
The company's recent earnings report beat analyst estimates, showcasing strong financial performance and positive outlook.
With a current stock price of $70.88, there may be an opportunity for investors to buy at a potentially undervalued level.
Edwards Lifesciences Co. operates in the structural heart disease and critical care monitoring sectors, which are essential and growing areas in the healthcare industry.
The company's moderate buy consensus rating and price target of $81.10 suggest positive sentiment and potential upside for investors.

Edwards Lifesciences
Bear Case

Investors should be bearish about investing in Edwards Lifesciences Co. for these reasons:

Edwards Lifesciences Co.'s stock has experienced a recent decline of 0.6%, indicating potential volatility and market uncertainty.
The company's price-to-earnings ratio of 30.55 and price-to-earnings-growth ratio of 2.57 may suggest a relatively high valuation compared to industry peers.
Insiders have sold a significant number of company shares in the last ninety days, potentially signaling lack of confidence or future challenges.
Several equities research analysts have issued hold ratings on the stock, indicating mixed opinions on its future performance.
The company's debt-to-equity ratio of 0.08 may raise concerns about its financial leverage and risk exposure.

EW Forecast - Frequently Asked Questions

: According to the research reports of 27 Wall Street equities research analysts, the average twelve-month stock price forecast for Edwards Lifesciences is $79.82, with a high forecast of $106.00 and a low forecast of $57.00.
: 27 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Edwards Lifesciences in the last twelve months. There are currently 15 hold ratings, 11 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" EW shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in EW, but not buy additional shares or sell existing shares.
: According to analysts, Edwards Lifesciences's stock has a predicted upside of 19.88% based on their 12-month stock forecasts.
: Over the previous 90 days, Edwards Lifesciences's stock had 7 downgrades and 3 upgrades by analysts.
: Edwards Lifesciences has been rated by research analysts at Baird R W, Bank of America, Barclays, Canaccord Genuity Group, Citigroup, Daiwa America, Daiwa Capital Markets, Deutsche Bank Aktiengesellschaft, Evercore ISI, Jefferies Financial Group, JPMorgan Chase & Co., Oppenheimer, Piper Sandler, Robert W. Baird, Royal Bank of Canada, Stifel Nicolaus, TD Cowen, The Goldman Sachs Group, Truist Financial, UBS Group, Wells Fargo & Company, and Wolfe Research in the past 90 days.
: Analysts like Edwards Lifesciences less than other "medical" companies. The consensus rating for Edwards Lifesciences is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how EW compares to other companies.